Roger Chammas
CV Lattes
GoogleMyCitations
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Coordenadoria de Serviços de Saúde (CSS). Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP) (Institutional affiliation for the last research proposal) Birthplace: Brazil
Roger Chammas, MD-PhD concluded his studies in Medicine (1988) and got his PhD degree in Biochemistry (1993) at Universidade de São Paulo, while working at the Ludwig Institute for Cancer Research (1989-1993). He specialized in Glycobiology at University of California, San Diego (1994-1997) and was a visiting researcher at Friedrich-Miescher Institute, Basel (1991), Harvard School of Public Health, Boston (1993), Universidade Federal de São Paulo (1998-1999); Moffitt Cancer Research Center, Tampa (2011-2012) and University of California, Davis (2019). Chammas is presently Full Professor of Oncology at Faculdade de Medicina da Universidade de São Paulo, where he has been working since 2000 and adjunct professor at the Dept of Chemistry at University of North Carolina, Charlotte, since 2016.Chammas serves as chair of the Center for Translational Research in Oncology, a research unit for both basic and translational cancer research at Instituto do Câncer do Estado de São Paulo, a specialized institute for cancer management and oncology teaching and research associated with Universidade de São Paulo. Chammas serves as academic editor for Plos One and Anais da Academia Brasileira de Ciências. His major interests are in the area of Cancer Biology (Biochemistry and Cancer Cell Biology), focusing in tumor progression, carbohydrate-dependent tumor markers and tumor microenvironment, as targets for combination therapy and molecular diagnostics through imaging in cancers. (Source: Lattes Curriculum)
- Cancer and heart: new paradigms of diagnosis and treatment, AP.TEM
Abstract
Despite of the uninterrupted development of new medications for the treatment of cancer, the survival rate continues low especially in those patients in the advanced stage of the disease. Recent observations show that new therapeutics increase the susceptibility for cardiovascular diseases, which turns out to be the treatment of cancer even more complex. Cardiac dysfunction due to cardi...
- Plan for use of the institutional overhead - ICESP, 2017, AP.RT.INST
Abstract
The vision of Instituto do Câncer do Estado de São Paulo is to constitute an Excellence Center for Total Cancer Care and Research. To reach this goal, it is critically necessary to invest in research and innovation. Our research activities are organized in order to favor the continued search for solutions to the problems experience by the cancer patient daily. (AU)
- General plan for the application of the institutional overhead, 2016-2017, AP.RT.INST
Abstract
One of the aims of the Instituto do Câncer do Estado de São Paulo (ICESP) is to constitute an Excellence Center for Research in Oncology, which should be internationally recognized. Investment in research activities is therefore necessary. Research activities are coordinated by two administrative offices, clinical research facility and the center for translational research in oncology. ...
- Accumulation of PHB1 is a common cellular response to different stressing stimuli and protects melanoma cells from er stress and the cytotoxic agent cisplatin, PUB.ART
Abstract
Melanoma is responsible for most deaths among all skin cancers and conventionalchemotherapy fails because of the development of chemoresistance. We usedproteomic analysis to identify cellular responses that lead to the chemoresistanceof human melanoma cell lines to cisplatin. A systems approach to the proteomicdata indicated the participation of specific cellular processes such as oxida...
(Only some records are available in English at this moment)
- Effect of miR-195 superexpression in the cargo of microRNAs present in extracellular vesicles secreted by human melanoma cells and in the regulation of sensibility to target-therapy through horizontal transfer of information, BP.MS
Abstract
Melanoma is considered the most aggressive form of skin cancer. About 60% of the patients harbor a mutation in the BRAF gene, resulting in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Combined targeted therapy with BRAF and MEK inhibitors is associated with significant improvement in progression-free survival and objective responses of patients with ad...
- Remodeling of omega 3 and omega 6 polyunsaturated fatty acids in extracellular vesicles released by Melanoma cells: changed response to radiotherapy?, BP.PD
Abstract
Melanoma is considered one of the most aggressive types of Cancer. Its relevance is increasing, as its incidence has increased rapidly around the world and there is still no effective therapy for metastatic disease. The conventional therapies such as chemotherapy and radiotherapy have not been effective in most cases due to intrinsic/extrinsic resistance observed in Melanoma cells. In t...
- Evaluation of the involvement of prohibitin 1 (PHB) in the activation of STAT3 in macrophages, BP.IC
Abstract
Macrophages are a major component of the tumor microenvironment and its presence is generally associated with a worse tumor prognosis, enhancing tumor growth, drug resistance and local immunosupression. Pro-tumoral macrophages generally display an anti-inflammatory profile. Prohibitin 1 (PHB) is a protein with varied functions, with the most well known activities being related to cell c...
- Involvement of PAFR activation during chemotherapy in the melanoma repopulation phenomenon, BP.MS
Abstract
One of the biggest challenges faced in cancer treatment is the process of tumor repopulation.In this process, cells that are refractory to therapy, are able to proliferate and reconstitute the tumor. Despite its clinical frequency and its contribution to treatment failure, the molecular and cellular events involved in this phenomenon are still poorly understood. The comprehension of the...
- Analysis of subpopulation of CD20 positive melanoma cells in response to chemotherapy agents, using radionuclide imaging, BP.DR
Abstract
Malignant melanoma is the most aggressive cancer among skin tumors. Both high tumor growth rate and high toxicity caused by the treatment contribute to the lower survival rate of melanoma patients, as compared with patients with other skin cancers. Although various drugs and molecules have been developed over the past few years, little efficiency was obtained in therapy so far. In this ...
(Only some records are available in English at this moment)
- Evaluation of PAFR activation in the survival response and chemoresistance of tumor cells exposed to hypoxia, BE.EP.MS
Abstract
Metastatic melanoma has been considered a clinical challenge due to its notorious chemoresistance. The understanding of molecular and cellular events that contributes to melanoma chemoresistance is important to improve current therapies and prevent tumor recurrence. Previous in vivo studies from our group showed that PAFR activation favors melanoma growth by protecting to cisplatin-indu...
- Development of peptides for the in vivo detection of M1 and M2 macrophages in the tumor microenvironment, BE.EP.PD
Abstract
The presence of high macrophage infiltration within solid tumors correlates with chemoresistance, metastasis, poor prognosis and shorter survival of patients. Strategies that can identify macrophages within the tumor microenvironment or reeducate these cells towards a proinflammatory phenotype can improve the therapies for cancer management. Macrophages are among the most abundant cells...
- Post-transcriptional regulation of PHB gene by RNA-binding proteins and microRNAs in human melanoma, BE.EP.PD
Abstract
Cutaneous melanoma is one epithelial tumor originates in melanocytes. This tumor represents 4% of malignant neoplasms of skin and it is considered an important public health problem because of its high progression to metastasis and treatment resistance. Previous studies of our group revealed the accumulation of prohibitin (PHB) in cell lines of human melanoma after treatment with cispla...
| 1 / 1 | Ongoing research grants |
| 13 / 10 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 39 / 23 | Completed scholarships in Brazil |
| 4 / 3 | Completed scholarships abroad |
| 59 / 39 | All research grants and scholarships |
| Associated processes | |
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
| Publications | 10 |
| Citations | 146 |
| Cit./Article | 14.6 |
| Data from Web of Science | |
LONGO MACHADO, CAMILA MARIA; SOUSA ANDRADE, LUCIANA NOGUEIRA; TEIXEIRA, VERONICA RODRIGUES; COSTA, FABRICIO FALCONI; MELO, CAMILA MORAIS; DOS SANTOS, SOFIA NASCIMENTO; NONOGAKI, SUELY; LIU, FU-TONG; BERNARDES, EMERSON SOARES; CAMARGO, ANAMARIA ARANHA; et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGF beta 1-induced macrophages. CANCER MEDICINE, v. 3, n. 2, p. 201-214, APR 2014. Web of Science Citations: 21.
CARNACHO, XIMENA; MACHADO, CAMILA LONGO; GARCIA, MARIA FERNANDA; GAMBINI, JUAN PABLO; BANCHERO, AGUSTINA; FERNANDEZ, MARCELO; ODDONE, NATALIA; ZANATTA, DANIELA BERTOLINI; ROSAL, CAROLINA; BUCHPIGUEL, CARLOS ALBERTO; et al. Technetium-99m-or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. ONCOLOGY, v. 92, n. 4, p. 229-242, 2017. Web of Science Citations: 4.
IKEMORI, RAFAEL YAMASHITA; LONGO MACHADO, CAMILA MARIA; FURUZAWA, KARINA MIE; NONOGAKI, SUELY; OSINAGA, EDUARDO; UMEZAWA, KAZUO; DE CARVALHO, MARCELO ALEX; VERINAUD, LIANA; CHAMMAS, ROGER. Galectin-3 Up-Regulation in Hypoxic and Nutrient Deprived Microenvironments Promotes Cell Survival. PLoS One, v. 9, n. 11, NOV 4 2014. Web of Science Citations: 23.
NOVAK‚ E.M.; METZGER‚ M.; CHAMMAS‚ R.; DA COSTA‚ M.; DANTAS‚ K.; MANABE‚ C.; PIRES‚ J.; DE OLIVEIRA‚ AC; BYDLOWSKI‚ SP. Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Therapy, v. 10, n. 23, p. 1992-1997, 2003.
DE AGUIAR, RODRIGO BARBOSA; PARISE, CAROLINA BELLINI; TEIXEIRA SOUZA, CAROLINA ROSAL; BRAGGION, CAMILA; QUINTILIO, WAGNER; MORO, ANA MARIA; NAVARRO MARQUES, FABIO LUIZ; BUCHPIGUEL, CARLOS ALBERTO; CHAMMAS, ROGER; DE MORAES, JANE ZVEITER. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Letters, v. 371, n. 2, p. 151-160, 2016. Web of Science Citations: 10.
KE, WEINA; HONG, ENPING; SAITO, RENATA F.; RANGEL, MARIA CRISTINA; WANG, JIAN; VIARD, MATHIAS; RICHARDSON, MELINA; KHISAMUTDINOV, EMIL F.; PANIGAJ, MARTIN; DOKHOLYAN, V, NIKOLAY; et al. RNA-DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-B in human cells. Nucleic Acids Research, v. 47, n. 3, p. 1350-1361, FEB 20 2019. Web of Science Citations: 8.
ONUCHIC, ANA CLAUDIA; MACHADO, CAMILA M. L.; SAITO, RENATA F.; RIOS, FRANCISCO J.; JANCAR, SONIA; CHAMMAS, ROGER. Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma. Mediators of Inflammation, 2012. Web of Science Citations: 27.
SAITO, RENATA DE FREITAS; TORTELLI, JR., THARCISIO CITRANGULO; JACOMASSI, MAYARA D'AURIA; OTAKE, ANDREIA HANADA; CHAMMAS, ROGER. Emerging targets for combination therapy in melanomas. FEBS Letters, v. 589, n. 22, SI, p. 3438-3448, NOV 14 2015. Web of Science Citations: 16.
RAMOS CIRILO, PRISCILA DANIELE; DE SOUSA ANDRADE, LUCIANA NOGUEIRA; SILVA CORREA, BRUNA RENATA; QIAO, MEI; FURUYA, TATIANE KATSUE; CHAMMAS, ROGER; FERRAZ PENALVA, LUIZ OTAVIO. MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. BMC CANCER, v. 17, NOV 10 2017. Web of Science Citations: 9.
VASCONCELOS, RENATA OTTES; SERINI, SIMONA; DE SOUZA VOTTO, ANA PAULA; TRINDADE, GILMA SANTOS; FANALI, CATERINA; SGAMBATO, ALESSANDRO; CALVIELLO, GABRIELLA. Combination of omega-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study. Melanoma Research, v. 29, n. 3, p. 270-280, JUN 2019. Web of Science Citations: 1.
FERREIRA CARDOSO, ANA CAROLINA; DE SOUSA ANDRADE, LUCIANA NOGUEIRA; BUSTOS, SILVINA ODETE; CHAMMAS, ROGER. Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments. FRONTIERS IN ONCOLOGY, v. 6, MAY 23 2016. Web of Science Citations: 27.
CORREA, MARIANGELA; MACHADO JUNIOR, JOEL; CARNEIRO, CÉLIA R. W.; PESQUERO, JOÃO BOSCO; BADER, MICHAEL; CHAMMAS, ROGER; TRAVASSOS, LUIZ RODOLPHO RAJA GABAGLIA. Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. International Journal of Cancer, v. 114, n. 3, p. 356-363, Apr. 2005.
(References retrieved automatically from State of São Paulo Research Institutions)
MELO, Fabiana Henriques Machado de. Exploração funcional do processo de glicosilação aberrante em tumores: mecanismos envolvidos na atividade pró-migratória de galectina-3. 2006. Tese (Doutorado) – Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
TEIXEIRA, Veronica Rodrigues. Mecanismos associados à perda de expressão do gene de galectina-3 em um modelo de progressão de melanoma murino. 2007. Tese (Doutorado) – Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
SAITO, Renata de Freitas. Indução de estresse de retículo endoplasmático como estratégia de quimiossensibilização de melanoma. 2014. Tese (Doutorado) – Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
OTAKE, Andréia Hanada. "Papel de dissialogangliosídios na proliferação e morte celular induzida de melanócitos e melanomas in vitro". 2006. Tese (Doutorado) – Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
ANDRADE, Luciana Nogueira de Sousa. Evidência da dualidade funcional de galectina-3 no crescimento de melanoma murino. 2007. Tese (Doutorado) – Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
JUNIOR, Tharcisio Citrangulo Tortelli. Avaliação do papel de proibitina no desenvolvimento de resistência à cisplatina em linhagens de melanoma humano. 2008. Dissertação (Mestrado) - Faculdade de Medicina. Universidade de São Paulo (USP). São Paulo.
MOLÉCULA HÍBRIDA PARA DIAGNÓSTICO E /OU PROGNÓSTICO DE DOENÇAS CRÔNICO-DEGENERATIVAS, INFECCIOSAS E DO DESENVOLVIMENTO PI0501095-0 - Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Universidade de São Paulo (USP). Roger Chammas; Fabiana Henriques Machado de Melo; Diego Alberto Butera Wadsworth; Ana Maria Moura da Silva - February 2005, 24